ANI Pharmaceuticals(ANIP) ZACKS·2025-04-23 13:30Market Overview - The U.S. stock market is expected to remain volatile due to the unresolved trade war with China, leading to uncertainty among investors regarding the near-term economic and policy outlook [1] Investment Strategy - A curated portfolio of low-beta stocks is recommended as a strategy to navigate market volatility, providing resilience and foresight for investors [2] - Stocks identified as potential investments include ANI Pharmaceuticals, Inc. (ANIP), Stride Inc. (LRN), 908 Devices Inc. (MASS), and Contango ORE, Inc. (CTGO) [2] Stock Analysis ANI Pharmaceuticals, Inc. (ANIP) - ANI Pharmaceuticals is a diversified biopharmaceutical company focused on affordable, premium-quality medicines, recently launching Nitazoxanide Tablets, 500 mg, and benefiting from upward earnings estimate revisions for 2025 [7] Stride Inc. (LRN) - Stride is positioned for long-term success by innovating educational experiences through technology-enabled solutions, supported by increasing demand for school choice and a focused growth strategy [8] 908 Devices Inc. (MASS) - 908 Devices is concentrating on handheld devices for drug threats and border security, experiencing rapid sales growth and aiming for profitability by 2026 after divesting a less profitable business [9] Contango ORE, Inc. (CTGO) - Contango is a gold explorer with increasing net operating cash flows from the Manh Choh production, expecting higher cash flows linked to spot gold prices in fiscal 2025 and 2026 [10] Screening Criteria - Stocks were screened based on a beta between 0 and 0.6, ensuring lower volatility than the market, with additional criteria including positive price movement over the last month, average trading volume greater than 50,000, a minimum price of $5, and a Zacks Rank of 1 (Strong Buy) [5][6]